ArticleProceedings (Baylor University. Medical Center)2024
Treatment in persistent genital arousal disorder: a scoping review.
Article in Proceedings (Baylor University. Medical Center), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Persistent genital arousal disorder (PGAD) is a rare condition characterized by unwanted and distressing symptoms of arousal and dysesthesia. The aim of this scoping review was to map the current state of PGAD management, identify gaps in the literature, and understand patient perspectives. Methods: We completed a scoping review following guidelines from the Joanna Briggs Institute and the Preferred Reporting Items for Systematic Reviews and Meta Analyses Scoping Reviews extension. A systematic literature search for articles pertaining to PGAD/genito-pelvic dysesthesia (GPD) was conducted in August 2023 via Medline, Embase, Scopus, and Web of Science. The search returns were deduplicated and the remaining titles and abstracts were screened for inclusion. General publication characteristics and treatment data were extracted from the included publications via a pilot-tested Google form. All screening and extraction were completed in a masked, duplicate fashion. Results: Findings from our scoping review revealed a scarcity of systematic research, limited evidence-based data, and the importance of addressing both physical and psychiatric concerns. Our sample included 46 publications from an initial pool of 636 returns. Case studies were the most common study design. Thirty-three studies examined medication, either alone or as part of a treatment regimen. Selective serotonin reuptake inhibitors were the most used medication, followed by pramipexole and carbamazepine. Seven studies used a surgical or procedural intervention. Treatment with pelvic floor Botox was the most common procedure. Patient perspectives in the included case studies highlighted themes of shame, suicidal ideation, social isolation, decreased sleep, and overall decline in quality of life. Conclusion: The findings from our study emphasize patients' distressing and psychiatric symptoms, indicating a need to improve treatment regimens, using both evidence-based research outcomes and patient-reported outcomes. Management for PGAD/GPD lacks a standardized framework, indicating a need for further research and the development of clinical practice guidelines to improve patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.